Prognostic value of long non-coding RNA plasmacytoma variant translocation1 in human solid tumors: A meta-analysis

Plasmacytoma variant translocation 1 (PVT1) is highly expressed in a variety of cancer tissues and is related to the clinicopathological features and prognosis. However, the prognostic value of PVT1 is still controversial. Therefore, this systematic evaluation and meta-analysis were performed to evaluate the relationship between PVT1 expression and clinicopathological features. PubMed, EMBASE, Web of science, and Cochrane library databases were searched for literature collection according to inclusion criteria and exclusion criteria. The pooled hazard ratios (HRs) or odds ratios (ORs) were used to evaluate the association between PVT1 expression and overall survival, tumor size, tumor–node–metastasis (TNM) stage, lymph node metastasis, and distant metastasis. A total of 39 articles including 3974 patients were included in the study. The results showed that the expression of PVT1 was closely related to the overall survival rate of cancers (HR = 1.64, 95% confidence interval [CI]: 1.50–1.78, P < .000001). Subgroup analysis showed that the high expression of PVT1 was closely related to the low overall survival rate of patients with clear cell renal cell carcinoma, breast cancer, cervical cancer, colon cancer, epithelial ovarian cancer, gastric cancer, lung cancer, and osteosarcoma. In addition, the high expression of PVT1 was positively correlated with tumor size (OR = 1.50, 95% CI: 1.14–1.96, P = .004), TNM stage (OR = 3.39, 95% CI: 2.73–4.20, P < .00001), lymph node metastasis (OR = 2.60, 95% CI: 1.76–3.84, P < .00001), and distant metastasis (OR = 2.94, 95% CI: 1.90–4.56, P < .00001). PVT1 could serve as a marker for the size, TNM stage, metastasis, and prognosis of different type of cancers.